On Thursday, Shares of Endo International plc (NASDAQ: ENDP) showed the bearish trend with a lower momentum of -0.40% to $7.43. The company traded total volume of 510,045 shares as contrast to its average volume of 3.13M shares. The company has a market value of $1.68B and about 225.35M shares outstanding.
Endo International plc (ENDP) recently stated fourth-quarter 2018 financial results.
CONSOLIDATED RESULTS:
Total revenues were $786.0M in fourth-quarter 2018 contrast to $769.0M during the same period in 2017. This increase was mainly attributable to continued strong growth in the U.S. Branded – Sterile Injectables segment and the Specialty Products portfolio of our U.S. Branded – Specialty & Established Pharmaceuticals segment. In addition to the continued strong underlying performance of our core areas of growth, the fourth quarter increase in these areas reflects a benefit from the timing of shipments contrast to prior year. These factors were partially offset by competitive pressures in the U.S. Generic Pharmaceuticals segment and the divestiture of the Company’s Mexican business, Somar.
GAAP net loss from continuing operations in fourth-quarter 2018 was $265.0M contrast to GAAP net loss from continuing operations of $272.0M during the same period in 2017. This result was mainly attributable to an overall reduction in operating expenses, counting the impact of lower litigation-related charges and research and development expenses, partially offset by higher asset impairment charges. GAAP diluted net loss per share from continuing operations in fourth-quarter 2018 was $1.18 contrast to GAAP diluted net loss per share from continuing operations of $1.22 in fourth-quarter 2017.
Adjusted income from continuing operations in fourth-quarter 2018 was $175.0M contrast to $174.0M in fourth-quarter 2017. Adjusted diluted EPS from continuing operations in fourth-quarter 2018 was $0.75 contrast to $0.77 in fourth-quarter 2017.
2019 FINANCIAL GUIDANCE:
For the twelve months ending December 31, 2019, at current exchange rates, Endo is providing guidance on revenue, adjusted diluted EPS from continuing operations and adjusted EBITDA from continuing operations. The Company estimates:
- Total revenues to be between $2.76B and $2.96B; Adjusted diluted EPS from continuing operations to be between $2.00 and $2.25; and Adjusted EBITDA from continuing operations to be between $1.24B and $1.34B.
BALANCE SHEET, LIQUIDITY AND OTHER UPDATES:
As of December 31, 2018, the Company had $1.10B in unrestricted cash; debt of $8.30B; net debt of about $7.10B and a net debt to adjusted EBITDA ratio of 5.2.
Fourth-quarter 2018 cash offered by operating activities was $70.0M, contrast to $132.0M of net cash offered by operating activities during fourth quarter 2017.
The Company offered net profit margin of -35.00% while its gross profit margin was 44.60%. ROE was recorded as 524.30% while beta factor was 1.14. The stock, as of recent close, has shown the weekly downbeat performance of -0.80% which was maintained at 2.19% in this year.
